CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
NVIDIA
NVDA
|
$40.6M |
| 2 |
Apple
AAPL
|
$9.08M |
| 3 |
Applied Materials
AMAT
|
$5.39M |
| 4 |
Arista Networks
ANET
|
$5.26M |
| 5 |
Amphenol
APH
|
$5.14M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Keurig Dr Pepper
KDP
$39.3B
| $274K | 0.04% |
8,150
+1,891
| +30% | +$63.5K |
|
202
Verizon
VZ
$185B
| $269K | 0.04% |
6,512
-1,929
| -23% | -$79.6K |
|
203
Iovance Biotherapeutics
IOVA
$792M
| $264K | 0.04% |
32,876
-20,832
| -39% | -$167K |
|
204
Vericel Corp
VCEL
$1.75B
| $262K | 0.04% |
5,709
-3,575
| -39% | -$164K |
|
205
Trade Desk
TTD
$26.5B
| $261K | 0.04% |
2,677
+670
| +33% | +$65.4K |
|
206
Myriad Genetics
MYGN
$642M
| $260K | 0.04% |
10,634
-6,606
| -38% | -$162K |
|
207
Charter Communications
CHTR
$36.1B
| $259K | 0.04% |
866
+211
| +32% | +$63.1K |
|
208
Caterpillar
CAT
$195B
| $257K | 0.04% |
+773
| New | +$257K |
|
209
Paychex
PAYX
$49B
| $257K | 0.04% |
2,164
+535
| +33% | +$63.4K |
|
210
Janux Therapeutics
JANX
$1.37B
| $255K | 0.04% |
6,090
-3,653
| -37% | -$153K |
|
211
Intellia Therapeutics
NTLA
$1.22B
| $254K | 0.04% |
11,333
-7,141
| -39% | -$160K |
|
212
IBM
IBM
$225B
| $246K | 0.03% |
1,420
-413
| -23% | -$71.4K |
|
213
Fortrea Holdings
FTRE
$909M
| $245K | 0.03% |
10,504
-6,593
| -39% | -$154K |
|
214
Pfizer
PFE
$142B
| $245K | 0.03% |
8,746
-2,591
| -23% | -$72.5K |
|
215
Protagonist Therapeutics
PTGX
$3.66B
| $239K | 0.03% |
6,891
-4,301
| -38% | -$149K |
|
216
Kraft Heinz
KHC
$30.8B
| $235K | 0.03% |
7,301
+1,829
| +33% | +$58.9K |
|
217
Vera Therapeutics
VERA
$1.44B
| $233K | 0.03% |
6,427
-3,690
| -36% | -$134K |
|
218
Beam Therapeutics
BEAM
$1.65B
| $232K | 0.03% |
9,906
-6,013
| -38% | -$141K |
|
219
Verisk Analytics
VRSK
$37B
| $231K | 0.03% |
858
+211
| +33% | +$56.9K |
|
220
Old Dominion Freight Line
ODFL
$31.5B
| $231K | 0.03% |
1,306
+344
| +36% | +$60.8K |
|
221
Amphastar Pharmaceuticals
AMPH
$1.43B
| $230K | 0.03% |
5,745
-3,501
| -38% | -$140K |
|
222
Rocket Pharmaceuticals
RCKT
$350M
| $230K | 0.03% |
10,666
-6,699
| -39% | -$144K |
|
223
Diageo
DEO
$61.5B
| $228K | 0.03% |
1,810
-2,644
| -59% | -$333K |
|
224
Structure Therapeutics
GPCR
$1.16B
| $226K | 0.03% |
5,753
-3,623
| -39% | -$142K |
|
225
Electronic Arts
EA
$42.9B
| $223K | 0.03% |
1,602
+396
| +33% | +$55.2K |
|